middle.news
How Imugene’s Azer-cel Trial and $25M Raise Could Reshape Lymphoma Treatment
1:02pm on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
How Imugene’s Azer-cel Trial and $25M Raise Could Reshape Lymphoma Treatment
1:02pm on Wednesday 25th of February, 2026 AEDT
Key Points
Net loss reduced by 22% to $37.8 million
Azer-cel Phase 1b trial shows 82% overall response rate in tough lymphoma cases
FDA validates key azer-cel trial design and regulatory pathway
Expanded trial cohort to CAR T-naïve lymphoma patients with 83% early response
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMUGENE (ASX:IMU)
OPEN ARTICLE